Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
RUPERT RESOURCES LTD.	RUP	Toronto S.E. +5 Other	51,023	3.92 CAD	Stock
RUPERT RESOURCES LTD.	R05	Deutsche Boerse AG	-	2.58 EUR
RUPERT RESOURCES LTD.	RUP	Toronto S.E.	55,704	3.92 CAD
RUPERT RESOURCES LTD.	R05	Börse Stuttgart	-	2.58 EUR
RUPERT RESOURCES LTD.	RUPRF	OTC Markets	5,084	2.9 USD
RUPERT RESOURCES LTD.	R05	BOERSE MUENCHEN	110	2.74 EUR

News (100)

Transcript : Evotec SE, Nine Months 2023 Earnings Call, Nov 08, 2023	11-08
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer	11/09/23	PR
Flagship Pioneering Announces Appointment of Rupert Vessey as Chief Scientist	14/07/23	AQ
Transcript : Bristol-Myers Squibb Company, Q4 2022 Earnings Call, Feb 02, 2023	02/02/23
BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	31/01/23	AQ
Bristol-Myers Squibb Company Announces Resignation of Dr. Rupert Vessey, Executive Vice President, Research and Early Development, Effective July 3, 2023	31/01/23	CI
BIO-TECHNE CORP : Results of Operations and Financial Condition, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	01/11/22	AQ
Immatics N : and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs - Form 6-K	02/06/22	PU
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs	02/06/22	BU
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs	02/06/22	GL
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs	02/06/22	AQ
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology	12/05/22	GL
Transcript : Bristol-Myers Squibb Company Presents at Guggenheim Healthcare Talks \| Targeted Protein Degradation Day, Mar-16-2022 10:15 AM	16/03/22
Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16	09/03/22	BU
Alexandria Real Estate Equities, Inc. Announces Long-Term Lease With Bristol Myers Squibb for a New 427,000 RSF Innovative Research Hub at the Alexandria Point Mega Campus in the San Diego Cluster Market	02/03/22	PR
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb	01/03/22	PR
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies	10/01/22	BU
Transcript : Bristol-Myers Squibb Company - Analyst/Investor Day	16/11/21
Press Release dated November 12, 2021 – “Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021” - Form 6-K	12/11/21	PU
Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021	12/11/21	PR
BIO-TECHNE CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	29/10/21	AQ
Nereid Therapeutics : Announces Appointments of Laura Forese and Rupert Vessey to Its Board of Directors	25/10/21	PR
Transcript : Bio-Techne Corporation - Analyst/Investor Day	10/09/21
Bristol Myers Squibb Exercises Option to Develop Exscientia’s AI-designed, Immune-modulating Drug Candidate	18/08/21	BU
Exscientia : announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb	19/05/21	BU
Evotec : launches 'beLAB1407' to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb	07/05/21	AQ
Evotec : launches 'beLAB1407' to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb	06/05/21	EQ
Transcript : Bristol-Myers Squibb Company - Shareholder/Analyst Call	04/05/21
Evotec : launches 'beLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb	14/04/21	AQ
Evotec : launches “beLAB2122”, translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb	13/04/21	PU
Evotec : launches 'beLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb	13/04/21	EQ
Bristol Myers Squibb : Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry	08/12/20	BU
Bristol Myers Squibb : Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb	23/11/20	BU
BIO-TECHNE CORP : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	03/11/20	AQ
Bristol Myers Squibb : UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026	05/10/20	AQ
UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026	02/10/20	GL
Bristol Myers Squibb : UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026	02/10/20	BU
Bristol Myers Squibb : Completes Acquisition of Forbius	22/09/20	AQ
Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases	22/09/20	BU
Bristol Myers Squibb : Completes Acquisition of Forbius	21/09/20	BU
Obsidian Therapeutics : Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate	15/09/20	PR
Bio Techne : Annual Report FY 2020	14/09/20	PU
Transcript : Bristol-Myers Squibb Company Presents at Citi 15th Annual Biopharma Virtual Conference 2020, Sep-08-2020 12:15 PM	08/09/20
Bristol Myers Squibb : to Participate in Citi’s 15th Annual BioPharma Virtual Conference	02/09/20	BU
Bristol Myers Squibb : Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio	24/08/20	BU

123NextSee all

Companies (12)

LI-FT POWER LTD. 132 M $

Li-FT Power Ltd. is a Canada-based mineral exploration company. The Company is engaged in the acquisition, exploration, and development of lithium pegmatite projects located in Canada. The Companyâs projects include Yellowknife Lithium Project, Rupert P ...

RUPERT RESOURCES LTD. 588 M $

Rupert Resources Ltd. is a Canada-based gold exploration and development company. The Companyâs principal focus is Ikkari, which is a gold discovery in Northern Finland. Ikkari is part of the Companyâs Rupert Lapland Project, which also includes the P ...

BUSCANDO RESOURCES CORP 827 527 $

Buscando Resources Corp is a Canada-based exploration-stage company. The Company is engaged in the business of acquiring, exploring and developing natural resource properties located in Canada. ...

GREAT REPUBLIC MINING CORP. 252 800 $

Great Republic Mining Corp. is a Canada-based exploration-stage mining company. The Company is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. The Company is focused on developing economic precious ...

DEMESNE RESOURCES LTD. 567 698 $

Demesne Resources Ltd. is a Canada-based company involved in the acquisition and exploration of magnetite mineral properties. The Company is primarily focused on mineral properties located in British Columbia. The Company's sole property is the Star Proje ...

BANKS ISLAND GOLD LTD. 61 $

Banks Island Gold Ltd. is a Canada-based natural resource company. The Company is a gold producer with its operating mine in British Columbia, Canada. The Company is also engaged primarily in the acquisition, exploration, development and operation of mine ...

CLOUDBREAK DISCOVERY PLC 3 M $

Cloudbreak Discovery plc is a United Kingdom-based company, which is a natural resource project generator and is engaged in the royalty business. The Company's principal activity also includes acquisition of projects and royalties. The Company's primary o ...

ALLE COAL 9 M $

Allegiance Coal Limited is an Australia-based company that is engaged in the acquisition and exploration of coal tenements. It is focused on seaborne met coal mine development and operations with operating mines in southeast Colorado, Alabama, as well as ...

COLONIAL COAL INTERNATIONAL CORP. 369 M $

Colonial Coal International Corp. is a Canada-based exploration stage company. The Companyâs principal activities include the acquisition, exploration and development of coal properties located in Canada. The Company is also engaged in the acquisition o ...

FORTUNE MINERALS LIMITED 29 M $

Fortune Minerals Limited is a Canada-based development stage mining company. The Company is focused on advancing the vertically integrated NICO cobalt-gold-bismuth-copper project. The project is located 160 kilometers (km) northwest of the city of Yellowk ...

12Next

Insiders

Rupert Vessey

Rupert J. Vessey holds the position of Executive VP-Research & Early Development at Bristol Myers Squibb Co. He is also on the board of Bio-Techne Corp., PharmAkea, Inc., Sidecar Therapeutics, Inc. and Elstar Therapeutics, Inc. and Member of The Royal College of Physicians. In the past Rupert J. Vessey held the position of Senior VP-Early Development & Discovery Sciences at Merck & Co., Inc. and President-Research & Early Development at Celgene Corp. Dr. Vessey received a graduate degree, a doctorate and an undergraduate degree from the University of Oxford.

Gary Vessey

Benjamin Alastair Martin Vessey

David Vessey

David Vessey is currently a member of The Chartered Institute of Marketing.
Previously, he held the position of Chairman at Luminus Group Ltd.

Bret C. Vessey

Jane Vessey

Jane Vessey currently works at Greenoak Housing Association Ltd., as Vice Chairman, Ground Rents Income Fund PLC, as Independent Non-Executive Director from 2021, and Northern Trust Global Investments, as Independent Non-Executive Director.

Jack Vessey

Phillip Vessey

John Vessey

Richard Charles Vessey

Richard Charles Vessey was the founder of Synnovia Ltd.
(founded in 2002) and Bell Plastics Ltd.
(founded in 1987), where he holds the titles of Non-Executive Director and Director respectively.
Currently, Mr. Vessey is the Chairman of Oxford Technology Management Ltd.
(since 2006) and an Independent Director of Oxford Technology 3 VCT Plc (since 2006).
He is also a Director at Plastics Capital Trading Ltd.
and a Member of The UK Shareholders Association Ltd.
Mr. Vessey previously served as the Chief Executive Officer of Im-Pak Technologies Ltd., Chairman of Oxford Sensor Technology Ltd., Independent Non-Executive Director of Oxford Technology VCT Plc, and Non-Executive Director of Plastics Capital Ltd.
Mr. Vessey completed his undergraduate degree at Imperial College London and holds an MBA from Harvard Business School.

No results for this search